| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,106 | 0,116 | 17:21 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Boule Diagnostics AB: Boule Diagnostics AB resolves on a fully secured rights issue of approximately MSEK 93 with an over-allotment option of up to approximately MSEK 63 subject to approval by the Extraordinary General Meeting | 166 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 04.11. | Boule Diagnostics AB: Boule Diagnostics refocuses its operations on consumables, service and OEM - discontinues its instrument business | 181 | GlobeNewswire (Europe) | The Board of Directors of Boule Diagnostics AB (publ) ("Boule" or the "Company") has, following a strategic review, decided to discontinue the Company's instrument business. Boule will cease its own... ► Artikel lesen | |
| 23.10. | Earnings Call: Boule Diagnostics bricht nach Umsatzeinbruch im dritten Quartal ein | 1 | Investing.com Deutsch | ||
| 23.10. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q3 2026 | 165 | GlobeNewswire (Europe) | Challenges in the instrument business but good stability in sales of consumables and the OEM business
Quarter July-September 2026Net sales amounted to SEK 96.2 million (127.2), corresponding to a decrease... ► Artikel lesen | |
| 06.10. | Boule Diagnostics AB: Boule Diagnostics Strengthens Long-Term Strategic Collaboration in India | 213 | GlobeNewswire (Europe) | Boule Diagnostics AB and Q-Line Biotech Limited have updated the licensing agreement between the two parties relating to diagnostic reagents, consumables and hematology analyzers for India market. The... ► Artikel lesen | |
| 31.08. | Boule Diagnostics AB: Bulletin from the Extraordinary General Meeting August 31, 2026 in Boule Diagnostics | 304 | GlobeNewswire (Europe) | The Extraordinary General Meeting (the "EGM") resolved to approve a loan from one of the company's major shareholders, AB Grenspecialisten, in accordance with the Board of Directors' proposal. Complete... ► Artikel lesen | |
| BOULE DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 17.07. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q2 2026 | 245 | GlobeNewswire (Europe) | Quarter April-June 2026Net sales amounted to SEK 112.2 million (129.3), corresponding to a decrease of 13.3 percent. Organic sales growth amounted to -5.3 percent, currency effects amounted to -8.0... ► Artikel lesen | |
| 18.06. | Boule Diagnostics AB: Boule Diagnostics appoints new Chief Executive Officer | 738 | GlobeNewswire (Europe) | The Board of Directors at Boule Diagnostics has today appointed Johan Folkunger, Chief Executive Officer, effective June 22, 2026. Johan Folkunger succeeds Simonetta Tumbiolo, who has been serving... ► Artikel lesen | |
| 29.05. | Boule Diagnostics AB: Interim CEO at Boule Diagnostics | 248 | GlobeNewswire (Europe) | The board of directors at Boule Diagnostics has today appointed Simonetta Tumbiolo, currently Chief Commercial Officer Diagnostic, as Interim Chief Executive Officer, effective June 1 2026. As previously... ► Artikel lesen | |
| 13.05. | Boule Diagnostics AB: Bulletin from the Annual General Meeting May 13, 2026 in Boule Diagnostics | 391 | GlobeNewswire (Europe) | At the Annual General Meeting 2026 (the "AGM") it was resolved to adopt the balance sheets and profit and loss statements for the parent company and the group for the financial year 2025. The AGM resolved... ► Artikel lesen | |
| 28.04. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q1 2026 | 237 | GlobeNewswire (Europe) | Stable start to 2026
Quarter January-March 2026} Net sales amounted to SEK 101.6 million (112.9), corresponding to a decrease of 10.0 percent. Organic sales growth amounted to 3.0 percent, currency... ► Artikel lesen | |
| 11.02. | Boule Diagnostics AB: Boule Diagnostics Year-end report 2025 | 473 | GlobeNewswire (Europe) | Improved operating cash flowQuarter October-December 2025Net sales amounted to SEK 120.2 million (143.2), corresponding to a decrease of 16.0 percent. Organic sales growth amounted to -11.7 percent... ► Artikel lesen | |
| 30.12.25 | Boule Diagnostics AB: Boule Diagnostics appoints Michael af Winklerfelt as new CFO | 423 | GlobeNewswire (Europe) | Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals... ► Artikel lesen | |
| 22.12.25 | Boule Diagnostics AB: Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy | 254 | GlobeNewswire (Europe) | Boule Diagnostics, together with its Italian distribution partner A. Menarini Diagnostics, is proud to announce its selection as one of only three providers in a nationwide tender for hematology solutions... ► Artikel lesen | |
| 05.12.25 | Boule Diagnostics AB: Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter | 280 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Torben Nielsen, Chief Executive Officer, has decided to leave the company to pursue another professional opportunity. Under Torben's leadership, the company has... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 51,55 | -0,44 % | DZ BANK stuft Fresenius SE auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Aktienwert für Fresenius nach Zahlen zum dritten Quartal von 58 auf 65 Euro angehoben und die Einstufung auf "Kaufen" belassen. Die Partnerschaft... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,760 | +2,83 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,230 | -1,35 % | Siemens-Aktie: Wie viel Luft hat die Dividende nach dem Healthineers-Abschied? | Siemens als Dividendenwert? Mit knapp 2 Prozent Rendite wirkt der Konzern eher wie ein Wachstumswert im Anzug. Doch die Ausschüttung klettert Jahr für Jahr, und jetzt trennt sich Siemens auch noch von... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 63,88 | -0,17 % | BMO raises BrightSpring Health stock price target on LDD momentum | ||
| HEARTFLOW | 46,200 | +3,47 % | Heartflow stock tumbles despite strong growth beating Q3 expectations | ||
| LIFESTANCE HEALTH GROUP | 13,630 | +2,17 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 25,190 | +2,03 % | Privia Health Group, Inc.: Privia Health Reports Strong Results in the 2025 Performance Year of the Medicare Shared Savings Program | ||
| GERRESHEIMER | 32,060 | -2,85 % | Gerresheimer: Was Anleger vor dem Jahresfinale prüfen sollten | ||
| PROGYNY | 35,810 | +1,02 % | Rekorde bei Familienplanung: Progyny glänzt mit blitzsauberer Bilanz und massiven Rückkäufen | Hier an der Wall Street in New York wird oft das schnelle Geld gesucht. Doch die wahren Börsenperlen findet man häufig in lukrativen Nischen, in denen ein Unternehmen zum unverzichtbaren Marktführer... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 25,740 | -0,04 % | Procept BioRobotics outlines $390M-$410M 2026 revenue, while targeting positive adjusted EBITDA in Q4 | ||
| ALIGNMENT HEALTHCARE | 6,550 | +0,77 % | Alignment Healthcare falls 9% amid weakness in Medicare Advantage stocks | ||
| UNITEDHEALTH | 314,40 | +4,45 % | UnitedHealth-Aktie -15%: Washington zieht die Daumenschrauben an - trotzdem kaufen? | Es ist bislang eine rabenschwarze Woche für die UnitedHealth-Aktie. Am Dienstag und am Mittwoch brach der Kurs der größten privaten US-Krankenversicherung in Summe um -15% ein. Was steckt hinter dem... ► Artikel lesen | |
| DRAEGERWERK | 117,20 | +1,21 % | Drägerwerk Vz.: Darf man diesem Braten trauen? | Im Rahmen des am Mittwoch abgehaltenen Kapitalmarkttages stellte der Medizin- und Sicherheitstechnik-Spezialist Drägerwerk seine Ziele bis zum Jahr 2030 vor. Die Anleger quittierten das mit Käufen,... ► Artikel lesen | |
| GENEDX | 47,060 | -4,43 % | GeneDx Taps Everett Cunningham as CEO | ||
| CARL ZEISS MEDITEC | 32,060 | -0,62 % | Carl Zeiss Meditec-Aktie -3%: Jetzt die Reißleine ziehen? | Die Aktie von Carl Zeiss Meditec gab am Mittwoch zeitweise mehr als 3% nach, FMC verlor im Dax bis zu 2%. Beide Titel konnten sich damit der Stabilisierung am Gesamtmarkt nicht anschließen, Auslöser... ► Artikel lesen |